Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton
Related Experiment Video
Updated: Feb 6, 2026

Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence
Published on: March 12, 2020
Takashi Misawa1, Takuma Fujisato1, Yasunari Kanda1
1National Institute of Health Sciences Setagaya , Tokyo , 158-8501 , Japan . Email: misawa@nihs.go.jp ;
Abstract:
Estrogen receptors (ERs) are a family of nuclear receptors (NRs) that regulate physiological effects such as reproduction and bone homeostasis. It has been reported that approximately 70% of human breast cancers are hormone-dependent and ERα-positive. Recently, novel anti-breast cancer drugs based on different mechanisms of action have received significant attention. In this article, we have designed and synthesized a selective ER degradation inducer based on the diphenylheptane skeleton. Western blotting analysis revealed that PBP-NC10 degraded ERα through the ubiquitin-proteasome system. We also performed computational docking analysis to predict the binding mode of PBP-NC10 to ERα.
Insights
Researchers developed a novel drug, PBP-NC10, that targets and degrades estrogen receptor alpha (ERα) in breast cancer cells. This selective ER degrader works via the ubiquitin-proteasome system, offering a new therapeutic strategy for hormone-dependent cancers.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Estrogen receptors (ERs) are nuclear receptors regulating key physiological processes.
- Approximately 70% of human breast cancers are ERα-positive and hormone-dependent.
- Novel therapeutic strategies targeting ERs are crucial for breast cancer treatment.
Purpose of the Study:
- To design and synthesize a novel selective estrogen receptor degrader (SERD).
- To investigate the mechanism of action of the synthesized compound on ERα.
- To predict the binding interactions of the compound with ERα.
Main Methods:
- Chemical synthesis of a diphenylheptane-based compound.
- Western blotting to analyze protein degradation.
- Computational docking to predict binding modes.
Main Results:
- A selective ERα degradation inducer, PBP-NC10, was successfully synthesized.
- Western blotting confirmed that PBP-NC10 degrades ERα via the ubiquitin-proteasome system.
- Computational docking provided insights into the binding mode of PBP-NC10 to ERα.
Conclusions:
- PBP-NC10 is a novel selective ERα degrader with potential therapeutic applications.
- The ubiquitin-proteasome system is the mechanism by which PBP-NC10 induces ERα degradation.
- Further studies are warranted to explore PBP-NC10 as an anti-breast cancer agent.
Related Concept Videos
Carbon Skeletons
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Internal Receptors
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...
Skeleton and Calcium Homeostasis
Overview of the Axial Skeleton
The axial skeleton of the...

